Navigation Links
Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment
Date:10/28/2009

ALEXANDRIA, Va., and BOSTON, Oct. 28 /PRNewswire/ -- The final results of the PROVE3 study will be presented at this year's annual meeting of the American Association for the Study of Liver Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of sustained viral response in genotype 1 patients with HCV who failed prior treatment with pegylated interferon and ribavirin.

According to John McHutchison, MD, principal investigator for this study, "This was the first large scale study performed in nonresponders to our current standard of care, which evaluated retreating these patients with the addition of an HCV-specific protease inhibitor. Its importance is, therefore, the proof of principle that adding this potent direct anti-viral allowed us to cure approximately 50 percent of this patient population who have failed therapy and for which no other options currently exists."

The study included 453 patients, and the SVR rates in all treatment groups who received the telaprevir-based therapy were significantly higher than those who received peginterferon alfa-2a and ribavirin. All patients who received telaprevir and achieved virologic response maintained it for 48 weeks after the end of the treatment.

The drug in this nonresponder setting is currently undergoing phase 3 large-scale registration trials to confirm and further elucidate the findings of this current phase 2 study. "To sit across the desk from our hepatitis C patients and tell those that have not responded that with this retreatment strategy they have a 50 percent chance of being cured will be a huge message for patients and providers if confirmed in larger phase 3 clinical trials," concluded Dr. McHutchison.

Abstract title:

PROVE3 final results and 1-year durability of SVR with Telaprevir-based regimen in hepati
'/>"/>

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
3. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
4. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
7. Patients Receiving High Radiation at Cedars Sinai File Class Action Lawsuit
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
10. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
11. EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimers Disease Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... , Oct. 2, 2014 A new Insights ... entitled, " Adherence: why it,s so hard and what ... key research findings on medication adherence and lays out ... percent through new interventions by 2017. For the past ... focused on building the body of scientific knowledge available ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
... SAN DIEGO, Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... its academic founder and member of the Board of ... week.  He was a thoughtful leader with an incredible ... was matched by his terrific wit and disarming good ...
... N.Y., Jan. 6, 2012  VirtualScopics, Inc., (NASDAQ: ... the pharmaceutical, biotechnology and medical device industries, announced today ... from the NASDAQ Stock Market indicating that the Company,s ... consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 ...
Cached Medicine Technology:VirtualScopics Announces Receipt of Notice from Nasdaq 2VirtualScopics Announces Receipt of Notice from Nasdaq 3
(Date:10/2/2014)... PA (PRWEB) October 02, 2014 Social-Engineer, ... social engineering announced today it will host a complimentary ... The webinar will reveal the final outcome of the ... DEF CON 22 in Las Vegas and explore how ... social engineering attacks. To register for the webinar ...
(Date:10/2/2014)... The Business Intelligence Group today ... for Business program. The BIG Awards specialize in ... judging process scored by well-known and experienced leaders ... winners this year epitomize what is going right ... the Business Intelligence Group. “The sheer amount of ...
(Date:10/2/2014)... BamboofloorChina.com is a distinguished bamboo product ... great appreciation from the global customers in the past ... make more excellent items. All its online workers are ... clients. , The company has recently added a ... website. Furthermore, the company’s marketing specialist has announced that ...
(Date:10/2/2014)... Maureen Salamon ... News) -- Middle-aged women with a neurotic personality style ... developing Alzheimer,s disease, new research suggests. Tracking 800 ... those who were most anxious, jealous and moody -- ... stress had double the risk of developing Alzheimer,s compared ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2
... The Vatican has yet again been forced to revise ... a foreign trip. En route to Cameroon on March 17, ... of HIV. A transcript of the pope,s comments on the ... "risked" aggravating the problem.Jon O,Brien, president of Catholics for Choice, ...
... found levels of certain cytokines spiked during disease stage ... South Africa recently had the rare opportunity to follow ... and recovery in a 29-year-old lab worker who had ... particular, the researchers followed the trajectory of cytokines, a ...
... hypertension, obesity, study found , , WEDNESDAY, March 18 (HealthDay News) ... than whites, a long-running study shows. , "What we found ... and it is not a rare occurrence," said Dr. Kirsten ... issue of the New England Journal of Medicine . ...
... the care needs of a child dependent on technology is ... upon mothers to help everyone in the family adjust. However, ... the challenges of raising these children, a research study from ... its cues from me," one mother told Valerie Toly, PhD, ...
... clinicians to identify study participants could compromise the recruitment ... to address this conflict of interest in their Institutional ... associate professor of law at Georgia State University, studied ... 117 medical schools that received National Institutes of Health ...
... March 18 Cogdell Spencer Inc. (NYSE: ... has declared a quarterly dividend of $0.225 per common share ... March 31, 2009. The dividend covers the first quarter ... Cogdell Spencer Inc. (NYSE: CSA ) is a ...
Cached Medicine News:Health News:Pope Not Infallible on Condoms 2Health News:Course of West Nile Infection Charted 2Health News:Course of West Nile Infection Charted 3Health News:High Rate of Early Heart Failure Seen in Blacks 2Health News:High Rate of Early Heart Failure Seen in Blacks 3Health News:Mothers have key role in family life for children with technology dependencies 2Health News:Conflicts of interest in clinical research 2Health News:Cogdell Spencer Inc. Declares Quarterly Dividend 2
Large. 2.5 mm diameter blade. Angled up 45 degrees. Round handle....
3 mm curved blade. Round handle....
9 mm blade....
Storz Ear Knife Handle....
Medicine Products: